title: Fcγ receptor polymorphisms do not predict response to intravenous immunoglobulin in myasthenia gravis.
abstract: We studied 63 patients with myasthenia gravis (MG) requiring treatment with intravenous immunoglobulin, to determine if polymorphisms within the FCγR2A (rs1801274), FCγR2B (rs1050501), FCγR3A (rs396991), and FCγR3B (NA1/NA2) genes are correlated with response to treatment. There was no significant difference in any of the polymorphisms studied between responders and nonresponders. Patients with the FCγR2B-232I/I polymorphism had higher disease severity measured by the quatitative myasthenia gravis score (QMGS). There was no difference in the distribution of the FCγR2B-232 polymorphisms between the patients and 90 healthy controls. The finding of greater disease severity in patients with the FCγR2B-232I/I polymorphism requires confirmation in a larger population of patients with myasthenia gravis.
authors.affiliation: Division of Neurology, Department of Medicine, University Health Network, Toronto General Hospital, Toronto, Canada.
authors.forename: Carolina
authors.initials: C
authors.lastname: Barnett
authors.forename: Yakob
authors.initials: Y
authors.lastname: Grinberg
authors.forename: Mahdi
authors.initials: M
authors.lastname: Ghani
authors.forename: Ekaterina
authors.initials: E
authors.lastname: Rogaeva
authors.forename: Hans
authors.initials: H
authors.lastname: Katzberg
authors.forename: Peter
authors.initials: P
authors.lastname: St George-Hyslop
authors.forename: Vera
authors.initials: V
authors.lastname: Bril
mesh_terms: D000328:Adult; D000368:Aged; D016009:Chi-Square Distribution; D004576:Electromyography; D019054:Evoked Potentials, Motor / Q000187:drug effects; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000235:genetics / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000235:genetics* / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000188:drug therapy* / Q000473:pathology; D011110:Polymorphism, Genetic / Q000235:genetics*; D017452:Receptors, IgG / Q000235:genetics*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D017452:Receptors, IgG